News

AgroSpheres Named on Both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 Lists by TIME Magazine

AgroSpheres has been named on both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 lists. These prestigious awards are presented by TIME and Statista Inc., the leading statistics portal and industry ranking provider. The award lists were announced on March 25th, 2025, and can be viewed on TIME’s website.

Statista ranked the winners based on three evaluation criteria:

  • Positive environmental impact: The scoring is based on impact data such as the quality and impact of their product/service portfolio, as well as the expertise of their leadership team provided by HolonIQ
  • Financial strength: The scoring is based on the analysis of financial data points e.g., revenue, employee or funding information
  • Innovation drive: The scoring is based on the Patent Asset Index featured in LexisNexis® Intellectual Property Solutions

“Being recognized by TIME as one of the top GreenTech companies in both the U.S. and globally is a testament to the power of science-driven innovation in reshaping agriculture and our strong business fundamentals,” said Payam Pourtaheri, Co-Founder and CEO of AgroSpheres. “We have built a solid financial foundation to support the rapid commercialization of our bio-based solutions, ensuring long-term impact for growers and the environment. This recognition reinforces our mission to lead the way in the bio-based revolution.”

“Innovation drive and impact go hand in hand,” added Ameer Shakeel, AgroSpheres’ Co-Founder and CTO. “We have built an end-to-end technology platform, rooted in cutting-edge science, novel active ingredients and a strong intellectual property portfolio. Our advancements in encapsulation and delivery technologies are paving the way for greener, more effective crop protection solutions across the industry. As we scale our operations to commercialization, this honor from TIME highlights the growing momentum behind sustainable agriculture worldwide.”

In support of the research, Statista gathered data from company applications, annual reports, media monitoring, and other public sources. Additionally, Statista worked with specialized data partners HolonIQ and LexisNexis® Intellectual Property Solutions to further strengthen the data quality.

Statista publishes hundreds of worldwide industry rankings and company listings with high-profile media partners. This research and analysis service is based on the success of statista.com, the leading data and business intelligence portal that provides statistics, relevant business data, and various market and consumer studies and surveys.

Read more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation